Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ELAC1
REST API REST API
Homo sapiens
ELAC1 is differentially expressed in 189 experiments: 79 organism parts: trigeminal ganglion, blood, ... (77 more);, 119 disease states: normal, T-cell acute lymphoblastic leukemia, ... (117 more);, 59 cell types 237 cell lines 25 compound treatments and 59 other conditions.
Synonyms D29
Orthologs Elac1 (Rattus norvegicus)   RNZ1_BOVIN (Bos taurus)   F6TTD9_CIOIN (Ciona intestinalis)   TRZ1 (Saccharomyces cerevisiae)   elac1 (Danio rerio)   Elac1 (Mus musculus)   elac1 (Xenopus laevis)   ELAC1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term metal ion binding, tRNA processing, nucleus, hydrolase activity, endonuclease activity, endoribonuclease activity, producing 5'-phosphomonoesters, tRNA 3'-trailer cleavage
InterPro Term RNase_Z, Beta-lactamas-like
UniProt Accession Q9H777
Search EB-eye ENSG00000141642
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-11078, E-GEOD-15765, E-AFMX-5, E-GEOD-22541, E-MEXP-1251, ... (19 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-MTAB-62, ... (26 experiments)

Factor Value U/D Experiments
SW480
2
 E-MTAB-37, E-GEOD-18005
CCRFCEM
2
 E-MTAB-37, E-GEOD-24147
BT474
1
2
 E-MTAB-37, E-MTAB-62, E-MEXP-440
PC-3MM2
1
 E-MEXP-2172
RL952
1
 E-MTAB-37
SUDHL10
1
 E-MTAB-37
231 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, ... (29 experiments)

Factor Value U/D Experiments
human embryonic stem cell
3
 E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
epithelial cell
2
 E-MEXP-2034, E-GEOD-4483
macrophage
1
 E-GEOD-3982
squamous cell carcinoma
1
 E-GEOD-17347
naive B cell
1
 E-TABM-702
ADC
1
 E-GEOD-19188
53 more value(s).


Disease state

studied in E-MEXP-1922, E-GEOD-6872, E-GEOD-22529, E-GEOD-15960, E-GEOD-1577, ... (37 experiments)

Factor Value U/D Experiments
adrenocortical carcinoma
2
 E-GEOD-10927, E-TABM-311
Down syndrome, acute megakaryoblastic leukaemia
1
 E-MTAB-62
glioblastoma (undifferciated)
1
 E-MTAB-62
presymptomatic DMD
1
 E-MTAB-62
prostate cancer
1
 E-MTAB-62
squamous cell carcinoma
1
 E-MTAB-62
113 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-TABM-782, E-GEOD-5824, E-TABM-868, ... (19 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
 E-MEXP-1958, E-TABM-868
bacterial endotoxin
1
 E-GEOD-3284
propofol
1
 E-GEOD-4386
MIG control
1
1
 E-GEOD-15811
heregulin
1
 E-GEOD-6462
NaOH
1
1
 E-MEXP-2590
19 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
28
2
1
 E-GEOD-3494


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-MTAB-62

Disease staging
studied in E-GEOD-19743, E-GEOD-22148, E-GEOD-21138

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-MEXP-2340

Genotype
studied in E-GEOD-17476, E-MEXP-421, E-TABM-868, E-GEOD-18005, E-GEOD-3790, ... (7 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-TABM-127, E-GEOD-20540, E-GEOD-9764, ... (9 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-2069, E-GEOD-19519, E-GEOD-16363, ... (13 experiments)

Infection
studied in E-GEOD-12108

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-1309, E-GEOD-21750, E-GEOD-17636

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

RNAi
studied in E-GEOD-12438, E-GEOD-3697, E-MEXP-1857, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400

Stimulation
studied in E-GEOD-11886

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-33562, E-MEXP-973, E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-22541

Processing time: 0.258 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM